Dr Jan Petracek, aged 42, currently holds the following directorships and has held no other directorships in the past five years: Current directorships: European Pharminvent Services s.r.o. Pharminvent regulatory s.r.o. PrimeVigilance d.o.o. Beograd-Novi Beograd PrimeVigilance Inc. PRIMEVIGILANCE LIMITED PrimeVigilance Zagreb d.o.o. SOUND OPINION LIMITED Dr Jan Petracek holds 367,597 Ordinary Shares of 1 […]
Dr Jan Petracek, aged 42, currently holds the following directorships and has held no other directorships in the past five years:
| Current directorships: | European Pharminvent Services s.r.o.
Pharminvent regulatory s.r.o. PrimeVigilance d.o.o. Beograd-Novi Beograd PrimeVigilance Inc. PRIMEVIGILANCE LIMITED PrimeVigilance Zagreb d.o.o. SOUND OPINION LIMITED |
Dr Jan Petracek holds 367,597 Ordinary Shares of 1 penny each in the Company.
Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Dr Petracek’s appointment.
ENDS
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 503205 | |
| Peter George (Chairman) | ||
| Stephen Stamp (Chief Executive Officer) | ||
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
| Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
| James Black (Joint Broker) | ||
| N+1 Singer | Tel: +44 (0) 20 7496 3000 | |
| Alex Price (Joint Broker) | ||
| Consilium Strategic Communications – for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
| Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner |
ergomed@consilium-comms.com | |
| MC Services – for Continental European enquiries | Tel: +49 211 5292 5222 | |
| Anne Hennecke | ||
About Ergomed
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed’s fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: https://ergomedplc.com.
